Neurontin® (gabapentin) Capsules
Neurontin® (gabapentin) Tablets
Neurontin®(gabapentin) Oral Solution
Neurontin® (gabapentin) has anticonvulsant and analgesic action.
Neurontin® (gabapentin) Capsules, Neurontin® (gabapentin) Tablets, and Neurontin® (gabapentin) Oral Solution are supplied as imprinted hard shell capsules containing 100 mg, 300 mg, and 400 mg of gabapentin, elliptical film-coated tablets containing 600 mg and 800 mg of gabapentin or an oral solution containing 250 mg/5 mL of gabapentin.
Neurontin® (gabapentin) is indicated for the management of postherpetic neuralgia in adults.
Neurontin® (gabapentin) is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Neurontin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 - 12 years.
Media Articles Related to Neurontin (Gabapentin)
Epilepsy Surgery Gets High Marks From Patients in Survey
Source: MedicineNet Seizure Specialty [2015.02.27]
Title: Epilepsy Surgery Gets High Marks From Patients in Survey
Category: Health News
Created: 2/26/2015 12:00:00 AM
Last Editorial Review: 2/27/2015 12:00:00 AM
Study: Medtronic deep brain stimulation therapy for treatment-resistant epilepsy shows significant and sustained seizure reduction at five year
Source: Epilepsy News From Medical News Today [2015.02.23]
Medtronic plc has announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation...
Anavex confirms positive preclinical epilepsy data for ANAVEX 2-73
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.02.13]
Anavex Life Sciences Corp. has confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform drug...
Epilepsy drug shows promise for reducing stroke-induced brain damage
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.02.12]
A drug FDA-approved for treating epilepsy - retigabine - may also be effective for reducing brain damage following ischemic stroke, according to a new study.
LSU Health New Orleans research finds novel compound switches off epilepsy development
Source: Epilepsy News From Medical News Today [2015.01.30]
Researchers at the LSU Health New Orleans Neuroscience Center of Excellence have found that a novel compound they discovered helps curtail the onset and progression of temporal lobe epilepsy.
Published Studies Related to Neurontin (Gabapentin)
The effects of gabapentin on methadone based addiction treatment: a randomized
controlled trial. 
Gabapentin is a potentially useful drug in alleviating the hyperexcitatory
painful states in the control of opiate dependence in acute detoxification and
the stabilization phase. This study aim was to evaluate the effectiveness of
gabapentin adds-on methadone therapy on lowering the methadone... This drug leads to
relief of withdrawal symptoms and lower methadone consumption.
Rationale and design of a multicenter randomized clinical trial of extended
release gabapentin in provoked vestibulodynia and biological correlates of
intercourse pain and summative 24-hour pain... CONCLUSION: We will conduct the first multicenter RCT to confirm efficacy of an
Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification
individuals randomized to treatment with gabapentin or chlordiazepoxide... CONCLUSIONS: In ambulatory veterans with symptoms of alcohol withdrawal,
Oral gabapentin premedication for elderly patients undergoing intraocular
undergoing cataract surgery... CONCLUSIONS: Hence, premedication with oral gabapentin in these elderly patients
Results of a double-blind, placebo-controlled, fixed-dose assessment of
once-daily OROS® hydromorphone ER in patients with moderate to severe pain
associated with chronic osteoarthritis. 
moderate to severe pain associated with OA... CONCLUSIONS: OROS hydromorphone ER failed to achieve statistical significance for
Clinical Trials Related to Neurontin (Gabapentin)
The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section [Recruiting]
Gabapentin has been very effective at treating pain after knee and hip operations,
hysterectomies, and many other types of operations. A previous study at the investigators'
hospital found that a single pre-operative dose of 600mg gabapentin produced a significant
reduction in pain after caesarean section. However, 19% complained of sedation. The purpose
of this study is to see whether a reduced dose of gabapentin will produce a similar
improvement in pain scores while avoiding adverse effects such as sedation or dizziness. The
objective of this study is to compare the efficacy of a single pre-operative oral dose of
gabapentin 300mg, versus 600mg and placebo in women undergoing Cesarean section. The
investigators' hypothesis is that gabapentin 300mg will result in decreased pain scores
similar to gabapentin 600mg, but with reduced side effects.
Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes. [Recruiting]
Premenopausal women with breast cancer who receive endocrine therapy (e. g. tamoxifen) and/or
chemotherapy are at risk for experiencing premature menopause because of their treatment.
The resulting symptoms, most notably hot flashes, can cause significant detriment to a
patient's quality of life. Treatment for menopausal symptoms with the gold standard of
hormone replacement therapy is not done routinely as it is unclear whether it can increase
risk of tumor recurrence. In addition, many medical oncologists feel it is contraindicated
in this population, especially among women whose breast cancers have estrogen receptors.
This has lead to an increased interest in options other than estrogen replacement in the
treatment of hot flashes, though most investigations of alternative medications have shown a
Recent studies have suggested that non-drug treatments using alternative or complementary
therapies may be effective. Specifically, hypnosis has been promoted as a means to control
hot flashes, though it has not been tested in a randomized fashion. In accordance with the
National Cancer Institute's recent initiatives to expand the goals of clinical trials to
include symptom management studies, our purpose is to evaluate the role of complementary and
alternative therapies for improvement of symptoms in women with breast cancer. Specifically,
we plan to evaluate the use of hypnotherapy for the treatment of therapy-induced hot flashes
in breast cancer survivors. We intend to recruit 60 women into a pilot feasibility trial
comparing hypnotherapy to the drug gabapentin (Neurontin®) for the treatment of
therapy-induced hot flashes in eligible women who are receiving care at the Breast Health
Center. We have chosen gabapentin based on recent studies showing it may be an effective
non-estrogen treatment for this indication.
We will identify patients who are experiencing at least one daily hot flash as a result of
the treatment they received for their breast cancer for participation. When enrolled, they
will be randomized into either the treatment arm, in which they will receive daily
gabapentin, or the experimental arm, in which they will undergo weekly hypnotherapy.
Our study hypothesis is that hypnotherapy will be more effective than gabapentin in the
control of hot flashes in this population.
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children [Recruiting]
This study is a prospective, randomized, double blind, placebo controlled, crossover
clinical trial looking at whether gabapentin can provide symptom relief for chronic
irritability in neurologically impaired children. The investigators hypothesize gabapentin
ins beneficial and safe for children with chronic irritability that persists despite
identification and appropriate management of symptom sources.
Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients [Recruiting]
The aim of this project is to study the use of gabapentin in reducing benzodiazepine abuse
in methadone maintenance patients. A second aim is to study the effects of gabapentin on
craving, mood, anxiety, and sleep disturbance in methadone maintenance patients abusing
benzodiazepines. The proposed protocol is a randomized, double-blind, placebo-controlled
pilot outpatient trial of gabapentin in the treatment of benzodiazepine abuse in methadone
maintenance patients. All subjects will receive weekly manual-guided psychotherapy directed
at achieving abstinence and improving current functioning. The primary outcome measure,
benzodiazepine use, will be assessed weekly by a combination of self-report (time line
follow-back method) and urine toxicology. Associated psychological symptoms of craving,
mood, anxiety, and sleep disturbance, will be assessed by a combination of clinician and
The investigators hypothesize that individuals receiving methadone maintenance treatment who
are abusing (nonprescribed use) benzodiazepines have difficulty in reducing or discontinuing
benzodiazepine use because of the significant anxiety, mood, and sleep disturbance symptoms
that accompany reduction in use. Gabapentin, an anticonvulsant which has anxiolytic and
sedating properties, may alleviate the symptoms associated with a reduction in
benzodiazepine abuse and make the achievement of abstinence more likely when administered in
the setting of an active psychotherapy condition.
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study [Recruiting]
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently
approved in the United States for the treatment of adults with moderate-to-severe primary
Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy,
tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already
approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to
severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a
condition of the approval of HORIZANT tablets (NDA 022399).
Reports of Suspected Neurontin (Gabapentin) Side Effects
Drug Ineffective (392),
Feeling Abnormal (116),
Pain in Extremity (115),
Fatigue (96), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 38 ratings/reviews, Neurontin has an overall score of 6.03. The effectiveness score is 6.84 and the side effect score is 6.63. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Neurontin review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || difficulty sleeping because of nervous system prob|
|Dosage & duration:|| || 500 mg at bedtime taken daily for the period of 6 years|
|Other conditions:|| || thyroid disease, allergies|
|Other drugs taken:|| || thyroid medication|
|Benefits:|| || Helped to promote sleep without side effects, hangover or any of the other problems associated with other sleep medications. The sleep difficulty was caused by a horrible reaction to another medication called Celexa, which appeared to sensitize my nervous system even after the Celexa was stopped. Ever since taking the Celexa my nervous system has been exquisitely sensitive, with symptoms such as pain, heart palpitations, restless legs, and other such things that totally interrupted my ability to fall asleep and stay asleep.|
|Side effects:|| || None|
|Comments:|| || Used 400-500 mg at bedtime.|
Neurontin review by 53 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Chronic pain (neck and migraines)|
|Dosage & duration:|| || 300 mg. taken 3 times per day for the period of 2 years|
|Other conditions:|| || insomnia|
|Other drugs taken:|| || Seroquel, Maxalt, Fosamax|
|Benefits:|| || The course of treatment reduced the severity and the frequency of the neck pain and migraines by about 50%. |
|Side effects:|| || Dizziness and fatigue|
|Comments:|| || the dose was started small and raised gradually to monitor side effects. It was only moderately successful and the side effects were quite a challenge. It was used as a standard prophylactic treatmemt against frequent migraines. |
Neurontin review by 25 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Severe neck pain lasting 8-9 mons|
|Dosage & duration:|| || 1 every 12 hours (dosage frequency: have taken only one so far!) for the period of one|
|Other conditions:|| || Neck pain / severe headaches|
|Other drugs taken:|| || n/a|
|Benefits:|| || Well I just wanted to comment or get some incite on this medication. I was just proscribed this medication yesterday took first one before bed as doctor said and woke up this morning feeling like i had drank a case of beer i stumbled getting up out of bed then i felt like i was dying of thirst was just wondering how normal this was? Oh and i was very sleepy and unable to wake up till nearly noon i started to sober up. I have a 3yr old son that i stay home with so i need to be able to function. when i had spoke to my doctor about the problems i was having i told him that i did not want to be on anything strong i had previously been put on Vicodin, oxy-codone and flexeral i hated it i could not take care of my son i could not function im just trying to find a solution for my pain without being messed up.! See back in October of 2009 i fell backwards into a dresser corner while putting my sons clothes up in welkin closet had two possible fractures and two slipped disks was in a neck brace from oct-feb so please let me know if you have any idea what i can do my insurance will not cover physical therapy unfortunately .....|
|Side effects:|| || dizziness , sleepy , dry mouth very thirsty|
|Comments:|| || treatment was suppose to be to help control neck pain and headaches|
Page last updated: 2015-02-27